The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells
Authors:
Open Access
- 9 January 2009
- journal article
- research article
- Published by Elsevier in Fertility and Sterility
- Vol. 93 (4) , 1290-1298
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-γ ligand, pioglitazoneMolecular Human Reproduction, 2005
- Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginoneEuropean Journal of Cancer, 2004
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- Extracellular matrix in vascular morphogenesis and disease: structure versus signalTrends in Cell Biology, 2003
- Human Leiomyoma Smooth Muscle Cells Show Increased Expression of Transforming Growth Factor- 3 (TGF 3) and Altered Responses to the Antiproliferative Effects of TGFThe Journal of Clinical Endocrinology & Metabolism, 2001
- Halofuginone: From veterinary use to human therapyDrug Development Research, 2000
- Transforming growth factor-β3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferationFertility and Sterility, 2000
- Hospitalization costs associated with leiomyomaClinical Therapeutics, 1999
- The expression of transforming growth factor-beta s and TGF-beta receptor mRNA and protein and the effect of TGF-beta s on human myometrial smooth muscle cells in vitroMolecular Human Reproduction, 1997
- Inhibition of Collagen Synthesis, Smooth Muscle Cell Proliferation, and Injury-Induced Intimal Hyperplasia by HalofuginoneArteriosclerosis, Thrombosis, and Vascular Biology, 1997